Table 2.
Baseline characteristics of patients and treated lesions after propensity score matching
| Characteristics | TACE | SBRT | p value |
|---|---|---|---|
| n = 70 | n = 35 | ||
| Gender | 0.543 | ||
| Male | 62 (88.6) | 29 (83.0) | |
| Female | 8 (11.4) | 6 (17.0) | |
| Age in years | 66.8 ± 9.9 | 69.0 ± 8.1 | 0.514 |
| ECOG1 | 0.999 | ||
| 0 | 45 (64.3) | 23 (65.7) | |
| 1/2 | 25 (35.7) | 12 (34.3) | |
| Etiology of liver disease | 0.999 | ||
| Viral | 8 (11.4) | 4 (11.4) | |
| Non-viral | 62 (86.6) | 31 (88.6) | |
| Child Score | 6.4 ± 1.5 | 6.4 ± 1.3 | 0.952 |
| Child A | 40 (57.1) | 19 (4.3) | 0.836 |
| Child B | 30 (81.4) | 16 (45.7) | 0.836 |
| Previous treatmenta | 2 (2.9) | 29 (83.0) | < 0.001 |
| None | 68 (97.1) | 6 (17.1) | < 0.001 |
| Surgery | 1 (1.4) | 8 (22.9) | 0.879 |
| Sorafenib | 1 (1.4) | 1 (2.9) | 0.001 |
| TACE | 0 | 28 (80.0) | < 0.001 |
| Intrahepatic tumor expansion | 0.999 | ||
| Oligonodular | 13 (18.6) | 6 (17) | |
| Multifocal | 57 (81.4) | 29 (83) | |
| BCLC2 | 0.999 | ||
| B | 49 (70.0) | 24 (68.6) | |
| C | 21 (30.0) | 11 (31.4) | |
| Largest tumor diameter [cm] | 8.3 ± 4.1 | 8.4 ± 3.9 | 0.845 |
| Segmental PVT4 | 21 (30.0) | 11 (31.4) | 0.999 |
| Laboratory | |||
| Platelets [103/μl] | 211 ± 157 | 183 ± 131 | 0.217 |
| AST7 [U/l] | 98 ± 83 | 99 ± 66 | 0.742 |
| ALT8 [U/l] | 69 ± 61 | 55 ± 40 | 0.280 |
| Bilirubin [mg/dl] | 1.6 ± 1.5 | 1.8 ± 1.8 | 0.511 |
| Albumin [g/dl] | 3.6 ± 0.7 | 3.4 ± 0.5 | 0.109 |
| AFP15 [ng/ml] | 3255.4 ± 10,907.7 | 2279.8 ± 9386.5 | 0.435 |
| Technical data TACE3 and SBRT5 | |||
| TACE | |||
| cTACE6 | 70 (100.0) | ||
| Drug-eluting beads TACE | 0 | ||
| Number of TACE sessions | 2 ± 1 | ||
| Two TACE | 49 (70.0) | ||
| Three TACE | 21 (30.0) | ||
| SBRT | median (IQR14) | ||
| Total prescribed dose (TD) | 45 (42–50) Gy | ||
| EQD210,TD9 | 56 (54–83) Gy | ||
| Dmax10 | 53 (50–57) Gy | ||
| EQD210,Dmax11 | 82 (62–98) Gy | ||
| Dmean,liver 12 | 17 (14–25) Gy | ||
| EQD2Dmean,liver 13 | 20 (14–36) Gy | ||
aPatients treated with SBRT have received more than one treatment
Abbreviations: 1ECOG Eastern Cooperative Oncology Group, 2BCLC Barcelona Clinic Liver Cancer, 3TACE transarterial chemoembolization, 4PVT portal vein thrombosis, 5SBRT stereotactic body radiation therapy, 6cTACE conventional transarterial chemoembolization, 7AST aspartat aminotransferase, 8ALT alanine aminotransferase, 9EQD210,TD equieffective doses for 2 Gy fractions of the prescribed dose, 10Dmax Maximum point dose, 11EQD210,Dmax equieffective doses for 2 Gy fractions of the maximum point dose, 12Dmean,liver Mean liver dose, 13EQD2Dmean,liver equieffective doses for 2 Gy fractions of the mean liver dose, 14IQR interquartile range, 15AFP alpha-fetoprotein